Plasma (1 → 3)-β-d-glucan and suPAR levels correlate with neurocognitive performance in people living with HIV on antiretroviral therapy: a CHARTER analysis
Despite antiretroviral therapy (ART), people living with HIV (PLWH) have higher rates of non-AIDS disorders, such as neurocognitive (NC) impairment (NCI) than the general population. (1-3)-β-d-Glucan (BDG) is a fungal cell wall component which serves as a biomarker for gut barrier integrity failure and microbial and fungal translocation. The primary objective of this study was to determine whether higher plasma and cerebrospinal fluid (CSF) levels of BDG and suPAR were associated with NCI in PLWH. Paired blood and CSF samples were collected cross-sectionally from 61 male adult PLWH on ART (95% virally suppressed) who underwent a detailed NC assessment as part of the prospective CHARTER study between 2005 and 2015. BDG and soluble urokinase plasminogen activator receptor (suPAR) were measured in frozen blood and CSF samples while soluble CD14 (sCD14), intestinal fatty acid binding protein (IFABP), and CD4/CD8 ratio were measured in blood only. Spearman’s rho correlation analysis assessed associations between BDG, other biomarkers, and NC performance. Median BDG levels were 18 pg/mL in plasma (range 2–60 pg/mL) and 20 pg/mL in CSF (range 0–830 pg/mL). Higher levels of plasma BDG were associated with worse NC performance (Spearman’s rho = − 0.32; p = 0.013) and with the presence of NCI (p = 0.027). A plasma BDG cutoff of > 30 pg/mL was 30% sensitive and 100% specific for NCI. After adjusting for age, higher plasma suPAR levels were also associated with worse NC performance (p < 0.01). No significant associations were observed between the remaining biomarkers and the NC variables. Plasma levels of BDG and age-adjusted suPAR may be new biomarkers for the detection of NCI in PLWH on suppressive ART.
KeywordsCSF Plasma Neurocognitive impairment Microbial translocation Virally suppressed Non-AIDS events suPAR sCD14 IFABP BDG
This work was supported by funds from the following: HNRP developmental grant PST-HN68 (from parent NIMH grant MH062512), and grants from the National Institutes of Health: AI036214, DA026306, AI064086, MH081482, MH113477, K24 MH097673 and AI106039. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript N01MH022005, HHSN271201000036C, R01MH107345 K23DA037793 R01 DA 034362.
Compliance with ethical standards
The UCSD Human Research Protections Program approved the study protocol, consent, and all study-related procedures. All study participants provided voluntary, written informed consent before any study procedures were undertaken.
Conflict of interest
MH received grant funding from Gilead. YZ and MF are employees of Associates of Cape Cod. All other authors declare no conflict of interest.
Fungitell®, the FDA-cleared IVD kit used for the measurement of (1 → 3)-β-glucan in serum, does not have an indication for the diagnostic use of BG titers in CSF. The data presented here represents the research use only.
- Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69(18):1789–1799CrossRefGoogle Scholar
- Blackstone K, Moore DJ, Franklin DR, Clifford DB, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, Ellis RJ, Atkinson JH, Grant I, Heaton RK (2012) Defining neurocognitive impairment in HIV: deficit scores versus clinical ratings. Clin Neuropsychol 26(6):894–908CrossRefGoogle Scholar
- Heldt S, Prattes J, Eigl S, Spiess B, Flick H, Rabensteiner J et al (2018) Diagnosis of invasive aspergillosis in hematological malignancy patients: performance of cytokines, Asp LFD, and Aspergillus PCR in same day blood and bronchoalveolar lavage samples. J Infect 77(3):235–241CrossRefGoogle Scholar
- Hoenigl M (2019) Fungal translocation: a driving force behind the occurrence of non-AIDS events? Clin Infect Dis. https://doi.org/10.1093/cid/ciz215
- Hoenigl M, Raggam RB, Wagner J, Valentin T, Leitner E, Seeber K, Zollner-Schwetz I, Krammer W, Prüller F, Grisold AJ, Krause R (2013) Diagnostic accuracy of soluble urokinase plasminogen activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syndrome. Clin Biochem 46(3):225–229CrossRefGoogle Scholar
- Hoenigl M, Perez-Santiago J, Nakazawa M, Faria de Oliveira M, Zhang Y, Finkelman M et al (2016a) (1 → 3)-β-glucan: a biomarker for microbial translocation in individuals with acute or early HIV infection? Front Immunol 7:404Google Scholar
- Hoenigl M, de Oliveira MF, Perez-Santiago J, Zhang Y, Morris S, McCutchan AJ et al (2016b) (1 → 3)-beta-d-Glucan levels correlate with neurocognitive functioning in HIV-infected persons on suppressive antiretroviral therapy: a cohort study. Medicine (Baltimore) 95(11):e3162Google Scholar
- Hoenigl M, Moser C, Funderburg N, Bosch R, Kantor A, Zhang Y et al (2018) Soluble urokinase plasminogen activator receptor (suPAR) is predictive of non-AIDS events during antiretroviral therapy-mediated viral suppression. Clin Infect Dis. https://doi.org/10.1093/cid/ciy966
- McLaurin KA, Booze RM, Mactutus CF (2019) Diagnostic and prognostic biomarkers for HAND. J NeurovirolGoogle Scholar
- Mehraj V, Ramendra R, Isnard S, Dupuy FP, Ponte R, Chen J, Kema I, Jenabian MA, Costinuik CT, Lebouché B, Thomas R, Coté P, Leblanc R, Baril JG, Durand M, Chartrand-Lefebvre C, Tremblay C, Ancuta P, Bernard NF, Sheppard DC, Routy JP, Montreal Primary HIV Infection Study and Canadian HIV and Aging Cohort Study Groups, Milne C, Lavoie S, Friedman J, Duchastel M, Villielm F, Asselin F, Boissonnault M, Maziade PJ, Lavoie S, Milne M, Miaki NZ, Thériault ME, Lessard B, Charron MA, Dufresne S, Turgeon ME, Vézina S, Huchet E, Kerba JP, Poliquin M, Poulin S, Rochette P, Junod P, Longpré D, Pilarski R, Sasseville E, Charest L, Hamel A, Cloutier-Blais A, Massoud S, Chano F, Trottier B, Labrecque L, Fortin C, Hal-Gagne V, Munoz M, Deligne B, Martel-Laferrière V, Trottier B, Goyer ME, Teltscher M, de Pokomandy A, Cox J, Beauchamp E, Haraoui LP (2019) Circulating (1-->3)-beta-D-Glucan is associated with immune activation during HIV infection. Clin Infect DisGoogle Scholar
- Morris A, Hillenbrand M, Finkelman M, George MP, Singh V, Kessinger C, Lucht L, Busch M, McMahon D, Weinman R, Steele C, Norris KA, Gingo MR (2012) Serum (1-->3)-beta-D-glucan levels in HIV-infected individuals are associated with immunosuppression, inflammation, and cardiopulmonary function. J Acquir Immune Defic Syndr 61(4):462–468CrossRefGoogle Scholar
- Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, Ketchum PA, Finkelman MA, Rex JH, Ostrosky-Zeichner L (2004) Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 39(2):199–205CrossRefGoogle Scholar
- Oliveira I, Andersen A, Furtado A, Medina C, da Silva D, da Silva ZJ, et al (2012) Assessment of simple risk markers for early mortality among HIV-infected patients in Guinea-Bissau: a cohort study. BMJ Open 2(6). https://doi.org/10.1136/bmjopen-2012-001587. Print 2012
- Rasmussen LJ, Knudsen A, Katzenstein TL, Gerstoft J, Obel N, Jorgensen NR et al (2016) Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study. HIV Med 17(5):350–357CrossRefGoogle Scholar